ARVN Arvinas, Inc.

NASDAQ
$6.76

Arvinas, Inc. (ARVN) is expected to report earnings on February 2, 2027, before the market open. The consensus earnings estimate is a loss of $0.67 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.3% since its last earnings release on November 3, 2026.

Arvinas Missed Consensus Estimates
Tuesday, November 3, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.67)
Rev est $19.38M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $6.89

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Arvinas, Inc.

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.